

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/024,701	12/17/2001		Dennis Keith	13764-003001	6796
26161	7590	02/09/2004		EXAMINER	
FISH & RI		SON PC	PESELEV, ELLI		
225 FRANK	LIN ST			D. DED MUCDED	
BOSTON, I	MA 0211	0	ART UNIT	PAPER NUMBER	
				1623	

DATE MAILED: 02/09/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	·Application No.	Applicant(s)				
	10/024,701	KEITH ET AL.				
Office Action Summary	Examiner	Art Unit				
	Elli Peselev	1623				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period w. - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	16(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days fill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONET	ely filed s will be considered timely. the mailing date of this communication. O (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on	<u>.</u> .					
2a) ☐ This action is FINAL . 2b) ☑ This	action is non-final.					
3) Since this application is in condition for allowar	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	3 O.G. 213.				
Disposition of Claims						
4) ☐ Claim(s) 1-57 is/are pending in the application. 4a) Of the above claim(s) is/are withdray 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-57 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or	vn from consideration.					
Application Papers						
9) The specification is objected to by the Examine	r.					
10) The drawing(s) filed on is/are: a) acce	☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the	drawing(s) be held in abeyance. See	e 37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex	· · · · · · · · · · · · · · · · · · ·					
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priori	s have been received. s have been received in Applicati ity documents have been receive ı (PCT Rule 17.2(a)).	on No ed in this National Stage				
Attachment(s)		(PTO 412)				
1) Hotice of References Cited (PTO-892) 2) D Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) 🔲 Interview Summary Paper No(s)/Mail Da	te				
Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Informal P 6) Other:	atent Application (PTO-152)				

Application/Control Number: 10/024,701

Art Unit: 1623

Claims 1-21 and 36 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

It is not clear what is meant by the terminology "a cation from a salt" (claim 1).

It is not clear what is encompassed by the terminology "calcium acetate pH 6.1" (claim 36).

Claims 22-57 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for glycerol, does not reasonably provide enablement for polyhydric alcohol. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. The terminology "polyhydric alcohol" (claims 22, 29 and 53) is not limited to an alcohol having any specific weight or chain length and therefore encompasses an alcohol having 100 or more carbon atoms. There is a good reason to doubt that such an alcohol will be useful in the claimed methods.

Claims 1-3 and 5-21 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for polyethylene glycol or polyethylene glycol monomethyl ether, does not reasonably provide enablement for an organic precipitant. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims. The terminology "an organic precipitant" (claim 1) encompasses a large number of organic compounds. Since the specification fails to provide any guidance on how to choose the desired precipitants, it would take an undue

Application/Control Number: 10/024,701

Art Unit: 1623

amount of experimentation to determine which specific organic precipitant, with the exception of polyethylene glycol or polyethylene glycol monomethyl ether, will be useful in the instant invention.

Claims 51-52 are objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim a multiple dependent claim cannot depend from any other multiple dependent claims. See MPEP § 608.01(n).

Note that claims 51-52 depend from claim 46 which depends from claims 22 and 29.

Abbott et al (U.S. Patent No. 4,524,135), which discloses A-21978C cyclic peptides, including daptomycin and Schwartz et al (U.S. Patent No. 5,336,756), which discloses crystallization of cyclic lipopeptides are cited to show the state of the art.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elli Peselev whose telephone number is (571) 272-2751. The examiner can normally be reached on 9.00-5.30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Wilson can be reached on (571) 272-0661. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Page 4

Application/Control Number: 10/024,701

ontrol Number. 10/024,70

Art Unit: 1623

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Elli Peselev

ELLI PESELEV PRIMARY EXAMINER GROUP 1200